Provided by Tiger Trade Technology Pte. Ltd.

Protagonist Therapeutics

89.65
+2.322.66%
Post-market: 90.000.3500+0.39%18:37 EST
Volume:1.47M
Turnover:130.94M
Market Cap:5.60B
PE:124.48
High:90.18
Open:87.96
Low:87.54
Close:87.33
52wk High:93.25
52wk Low:33.70
Shares:62.52M
Float Shares:43.15M
Volume Ratio:1.95
T/O Rate:3.41%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.7202
EPS(LYR):4.47
ROE:7.80%
ROA:1.82%
PB:8.68
PE(LYR):20.06

Loading ...

Protagonist Therapeutics (PTGX): Assessing Valuation After Breakthrough Phase 2b Results and Johnson & Johnson’s Phase 3 Launch

Simply Wall St.
·
Oct 30

Protagonist Therapeutics price target raised to $88 from $76 at Truist

TIPRANKS
·
Oct 28

Truist Raises Price Target on Protagonist Therapeutics to $88 From $76, Keeps Buy Rating

MT Newswires Live
·
Oct 28

Truist Financial Sticks to Its Buy Rating for Protagonist Therapeutics (PTGX)

TIPRANKS
·
Oct 28

Protagonist Therapeutics: Promising Prospects and Increased Price Target Amidst Positive Study Data and Strategic Partnerships

TIPRANKS
·
Oct 28

Protagonist Therapeutics: Promising Drug Development and Strong Clinical Progress Justify Buy Rating

TIPRANKS
·
Oct 28

Protagonist Therapeutics Price Target Maintained With a $82.00/Share by BTIG

Dow Jones
·
Oct 28

Clear Street sees ‘unmatched commercial promise’ for Protagonist’s icotrokinra

TIPRANKS
·
Oct 27

Protagonist Therapeutics (PTGX): Assessing Valuation After Strong Multi-Year Shareholder Returns

Simply Wall St.
·
Oct 20

Protagonist Therapeutics Is Maintained at Buy by Citigroup

Dow Jones
·
Oct 17

Protagonist Therapeutics price target raised to $96 from $72 at Citi

TIPRANKS
·
Oct 17

Protagonist Therapeutics Director William D. Waddill Reports Disposal of Common Shares

Reuters
·
Oct 15

High Growth US Tech Stocks To Watch In October 2025

Simply Wall St.
·
Oct 14

Johnson & Johnson Q3 Preview: With Stock Near All-Time Highs, Here's What To Watch

Benzinga_recent_news
·
Oct 14

FDA Adds New Warning For Johnson & Johnson's Cancer Cell Therapy

Benzinga
·
Oct 13

BUZZ-Street View: Protagonist's 'main character' energy draws J&J to potential takeover talks

Reuters
·
Oct 13

Protagonist Therapeutics (PTGX) Gets a Buy from BMO Capital

TIPRANKS
·
Oct 13

Protagonist Therapeutics (PTGX) Gets a Buy from Truist Financial

TIPRANKS
·
Oct 13

Protagonist Therapeutics Inc : Bmo Raises Target Price to $112 From $72

THOMSON REUTERS
·
Oct 13

U.S. Stocks to Watch: MP Materials, Nvidia, AMD, Tesla, Alibaba, Fastenal, and More

Dow Jones
·
Oct 13